Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Osteologix Inc.

Division of Osteologix Holdings PLC

Latest From Paddock Laboratories LLC

FDA Rejects Arguments On Keeping Rx PEG Products Available

FDA responded to arguments in its proposed order denying drug firms’ requests to allow their RX polyethylene glycol 3350 products to remain on the market. Among the arguments, all rejected by FDA, was that a prescription PEG 3350 should be available for use by pediatric patients and that the product is not safe OTC for elderly consumers.

Consumer BioPharmaceutical

FDA Almost Ready To Close Door On Rx Versions Of MiraLAX

FDA drug center Director Janet Woodcock says the agency “concluded there is no genuine and substantial issues that precludes the withdrawal” of approval of ANDAs for generic Rx polyethylene glycol 3350 products. But FDA is allowing firms with the ANDAs 60 days to again argue their positions.

Consumer BioPharmaceutical

Apotex Takes It On The Chin As Judge Excoriates Chairman For Deceiving PTO

District judge says Apotex’s Bernard Sherman submitted results of experiments he never conducted to the Patent and Trademark Office; asserts that misconduct in the company’s suit against UCB constitutes an abuse of the patent system.

BioPharmaceutical United States

Pay-For-Delay Deals: FTC Wants Legislation To Go Beyond “Reason”

FTC Chair Ramirez backs Senate bill to make such agreements between brand and generic manufacturers presumptively illegal; attorney says companies should document the fair valuation of patent settlement deals before a judge.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Osteologix Holdings PLC
  • Senior Management
  • Philip Young, Pres. & CEO
    Baxter Phillips, III, Sr. Dir., Corp. Dev.
  • Contact Info
  • Osteologix Inc.
    Phone: (415) 955-2700
    425 Market St., Ste. 2230
    San Francisco, CA 94105